SAM
URGN icon

Smartleaf Asset Management’s UroGen Pharma URGN Stock Holding History

Smartleaf Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Hold
72
– – ﹤0.01% 3078
2025
Q4 		$1.67K Hold
72
– – ﹤0.01% 3037
2025
Q3 		$1.38K Buy
+72
New +$1.29K ﹤0.01% 2690

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Smartleaf Asset Management's URGN Position: Q1 2026 in Review

Smartleaf Asset Management held its UroGen Pharma (URGN) position steady in Q1 2026 at 72 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #3078.

Smartleaf Asset Management first reported a position in URGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.67K in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Smartleaf Asset Management held 72 shares of UroGen Pharma worth $1.22K as of Q1 2026.
  • Smartleaf Asset Management left its UroGen Pharma share count unchanged in Q1 2026.
  • UroGen Pharma made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3078 holding.
  • Smartleaf Asset Management first reported a position in UroGen Pharma in Q3 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's UroGen Pharma position peaked at $1.67K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.